Baroldi Joseph 4

What Happened Joseph Baroldi, EVP and Chief Business Officer of Ionis Pharmaceuticals (IONS), exercised stock option/derivative awards to acquire a total of 5,635 shares (3,866 shares at $56.78 and 1,769 shares at $32.60) on June 26, 2026, paying $277,180 in aggregate exercise cost. Those 5,635 shares were sold in the open market the same day at a weighted average price of $80.16, generating total gross proceeds of $451,699 (sale prices ranged $80.00–$80.52). The filing shows the related derivative instruments were converted/terminated upon exercise.

Key Details

• Date of transactions: June 26, 2026; Form 4 filed June 30, 2026 (timely).
• Options/derivatives exercised: 3,866 @ $56.78 (cost $219,511) and 1,769 @ $32.60 (cost $57,669); total exercise cost $277,180.
• Open-market sale: 5,635 shares @ weighted avg $80.16 = $451,699 (range $80.00–$80.52).
• Net proceeds before taxes/fees ≈ $174,519 (sale proceeds minus exercise cost).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person’s spouse on Nov 25, 2025. The sale price reported is a weighted average; the filer can provide per-trade price breakdown on request.
• Derivative/transaction codes: M = exercise/conversion of derivative; $0 disposal lines reflect conversion/termination of the derivative instruments upon exercise.

Context This was an option exercise immediately followed by an open-market sale of the same shares (common pattern for cashless exercises or where shares are sold to cover exercise cost). The sale was executed under a pre-established 10b5-1 plan adopted by the insider’s spouse, which can indicate preplanned, routine disposition rather than a spontaneous market-timing decision. This Form 4 is factual reporting of the exercise and sale; it does not by itself indicate the insider’s view of the company’s prospects.